Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy ( nt and expedites regulatory review ofd...)

Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy

nt and expedites regulatory review of drugs intended to address an unmet medical need for serious or life-threatening conditions. With Fast Track designation for PRO 140, Progenics can take advantage of several programs at FDA to streamline the regulatory review process and to work more closely with the Agency on product development plans.

(PGNX-C)

About the Company

Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward gastroenterology as well as the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development. The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. In March 2007, the Company submitted a New Drug Application to the United States Food and Drug Administration for the subcutaneous formulation of methylnaltrexone for patients suffering from opioid-induced constipation while receiving palliative care. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5, which has completed phase 1b clinical studies with positive results. In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. The Company is developing in vivo immunotherapies for prostate cancer, including a human monoclonal antibody directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA and has a recombinant PSMA vaccine is in phase 1
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

(Date:5/19/2013)... , May 19, 2013 The non-surgical ... low temperature radiofrequency (RF) energy is effective in ... or reduces the need for medication 10 years ... presented today at the Digestive Disease Week (DDW) ... Florida . "The sustained ...

(Date:5/18/2013)... The Open Paradigm Project, in collaboration ... Psychiatry , and leading organizations in the movement ... media campaign showcasing video testimonials by individuals negatively ... on pathology and illness rather than wellness and ... Association,s (APA) rollout of its latest revision of ...

(Date:5/17/2013)... , May 17, 2013 The power of ... important ways in which mankind depends on the plant ... Garden,s multifaceted exhibition Wild Medicine: Healing ... on view from May 18 through September 8, ... The featured exhibition,s many attractions include a re-creation ...

Breaking Medicine Technology:Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2 Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3 New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2 New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3 Wild Medicine On View at The New York Botanical Garden Through Sept. 8 2

[0] Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy [0] New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses [0] Wild Medicine On View at The New York Botanical Garden Through Sept. 8

... FOLD ) today announced that John F. Crowley ... Chairman in order to devote more time to interests related ... role as Executive Chairman, Mr. Crowley will continue to perform ... will advise the current Amicus management team on corporate strategy ...

... The board of directors of Eli Lilly and Company (NYSE: ... second quarter of 2011 of $0.49 a share on outstanding ... 10, 2011 to shareholders of record at the close of ... innovation-driven corporation, is developing a growing portfolio of pharmaceutical products ...

Cached Medicine Technology:Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman 2

Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman Lilly Declares Second-Quarter 2011 Dividend

(Date:5/20/2013)... Angeles, CA (PRWEB) May 20, 2013 Idol ... get bigger, thicker, darker and fuller eyelashes in a matter ... now available for online purchase with an extra pack offer ... Customers can easily access this offer on the Idol lash ... and showed to increase the eyelash density up to 82% ...

(Date:5/20/2013)... US Drug Watchdog says, "After talking with ... are now calling the transvaginal mesh failure issues the ... and the damages are literally beyond comprehension. We are ... women. According to the New York Times, in 2010, ... implanted vaginally to treat urinary incontinence. That was 2010 ...

(Date:5/20/2013)... 20, 2013 On May 14th, premiere ... testimonial about how one of its patients originally came ... after being diagnosed with giant papillary conjunctivitis. “Giant papillary ... the eye, and for one of our patients in ... allergy,” says the Medical Director of the Atlanta Vision ...

(Date:5/20/2013)... The Mesothelioma Victims Center says, "We are ... diagnosed with mesothelioma get shortchanged when it comes to ... members turned to a local personal injury law firm, ... and experienced mesothelioma lawyers in the nation. We also ... never even bother to explore their legal options, because ...

(Date:5/20/2013)... CA (PRWEB) May 20, 2013 ... MessageSolution, an industry leader in enterprise-class information archiving, ... Enterprise eDiscovery Platform 7.0, the latest release in ... all facets of the legal discovery lifecycle. MessageSolution ... in Los Angeles CA. , As the first ...

Breaking Medicine News(10 mins):Health News:Idol Lash Eyelash Growth Enhancer Now Offered Extra Pack for Limited Time Only at HealthCareSupplementz.com 2 Health News:US Drug Watchdog Now Urges Transvaginal Mesh Failure Victims With Erosion To Call Them For The Names And Contacts Of The Best Women Attorneys 2 Health News:Atlanta LASIK Practice Publishes a Patient’s Testimonial About Allergy to Contact Lenses 2 Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For The Names Of The Nation's Best Mesothelioma Lawyers-Better Compensation 2 Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For The Names Of The Nation's Best Mesothelioma Lawyers-Better Compensation 3 Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 2 Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 3 Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 4

[0] Idol Lash Eyelash Growth Enhancer Now Offered Extra Pack for Limited Time Only at HealthCareSupplementz.com [0] US Drug Watchdog Now Urges Transvaginal Mesh Failure Victims With Erosion To Call Them For The Names And Contacts Of The Best Women Attorneys [0] Atlanta LASIK Practice Publishes a Patient’s Testimonial About Allergy to Contact Lenses [0] Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For The Names Of The Nation's Best Mesothelioma Lawyers-Better Compensation [0] MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo

... ... New York, NY (PRWEB) February 11, 2009 -- What better time ... their health is in their own hands? ZocDoc, the service that ... they have added 40% more cancer screening appointment times this month. ...

... to have compassion for others , , WEDNESDAY, Feb. 11 (HealthDay ... ability to empathize with others, suggests a U.S. study involving ... sound played in a specific cage as negative by also ... cage. But a genetically different strain of mice that were ...

... drug pricing or a ,national health insurance exchange, , , ... of Americans support President Barack Obama,s anticipated overhaul of ... elements as government negotiation with drug companies to lower ... health insurance exchange, a new Harris Interactive/HealthDay ...

... Presented at the Society of Gynecologic Oncologists, 40th Annual ... and ROMA(TM) Over Existing ToolsMALVERN, Pa., Feb. 11 ... at the Society of Gynecologic Oncologists, 40th Annual Meeting ... test - in combination with CA125 blood test results ...

... HCA today announced that it intends to offer ... secured second lien notes due 2017 (the "Notes"). ... offering to repay existing indebtedness, which may include borrowings ... credit facilities. To the extent that proceeds from ...

... ... ------- ... +3.7% EUR7,089m +3.6%, Adjusted net income, excluding selected, ... EUR1,627m +13.9%, Adjusted EPS excluding EUR5.49 +6.2% ...

ZocDoc Joins the Fight Against Cancer Empathy Might Be in the Genes Poll Shows Strong Support for Obama Health Care Reforms Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer HCA Announces Offering of $300 Million Senior Secured Second Lien Notes Sanofi-aventis Delivers 2008 Results Above Guidance

Duet Lumbar Allografts are comprised of a raised cancellous inner core providing biomechanical properties for rapid healing. Specially designed instruments facilitate the insertion of Duet Allografts...

Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....

Seletz-Gelpi Laminectomy Retractor, self-retaining with arms bent at right angles....

Scoville-Haverfield Hemilaminectomy Retractor...

Medicine Products:

Duet Lumbar Allograft System Graftech Posterior Ramp Seletz-Gelpi Laminectomy Retractor Scoville-Haverfield Hemilaminectomy Retractor